Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies

NCT04648202 is registered in ClinicalTrials.gov with invoX Pharma Limited as lead sponsor.

NCT NCT04648202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04648202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies
Lead sponsor
invoX Pharma Limited
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 18, 2020
Completion date
March 1, 2026
Enrollment
82 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer